TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $40.67.

A number of analysts recently weighed in on TGTX shares. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. TD Cowen initiated coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target for the company. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Wednesday. Finally, JPMorgan Chase & Co. increased their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th.

Insider Buying and Selling

In related news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sean A. Power sold 10,021 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,358 shares of company stock worth $781,497. 10.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TGTX. NBC Securities Inc. grew its stake in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the period. Blue Trust Inc. grew its stake in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in shares of TG Therapeutics during the 2nd quarter worth approximately $35,000. ORG Wealth Partners LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth approximately $53,000. Finally, Values First Advisors Inc. acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth approximately $58,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Trading Up 1.4 %

NASDAQ TGTX opened at $29.55 on Tuesday. The company’s 50-day moving average price is $31.73 and its 200-day moving average price is $25.79. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a market cap of $4.60 billion, a PE ratio of -295.47 and a beta of 2.24. TG Therapeutics has a 12 month low of $12.84 and a 12 month high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. During the same period last year, the company earned $0.73 earnings per share. The firm’s revenue was down 49.4% compared to the same quarter last year. Equities research analysts forecast that TG Therapeutics will post 0.07 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.